What Sensus Healthcare (SRTS) Said on Its Q3 Earnings Call

Impact · against what's priced in

Sensus Healthcare shows a concerning trend of declining revenue despite higher shipment volumes, signaling a shift toward lower-priced models and a loss of its largest customer. However, the signing of two PE-backed groups with 450+ practices and upcoming reimbursement hikes in 2027 provide long-term scalability and growth catalysts.

SRTS−0.10

No priced-in read yet

In context

The 13% revenue drop to $6 million despite a 62.5% increase in unit shipments confirms a dangerous shift in product mix and customer concentration. This is partially offset by a significant gross margin expansion to 55% and the acquisition of two PE-backed groups representing over 450 practices.

• earnings
• healthcare
• SRTS
• dermatology
• gross margin
• medical devices
• medtech
• oncology
• reimbursement
• revenue decline

Search tags